Authors: Adenis, A Bonneterre, J Bonneterre, ME Pion, JM Vanlemmens, L Gladieff, L de Lafontan, B Martel, P Mihura, J Roche, H Gedouin, D Kerbrat, P Lesimple, T Bremond, A Devaux, Y Delecroix, V Fumoleau, P Maugard-Louboutin, C Namer, M Goudier, MJ Morice, F Montcuquet, P Schraub, S Coudert, B Fargeot, P de Gislain, C Mayer, F Bastit, P Chevallier, B Grandgirard, A Monnier, A Sun, X Clavere, P Ollivier, JP Rhein, B Roullet, B Datchary, J Audhuy, B Barats, JC Kohser, F Dides, S Ramos, R Cattan, A Eymard, JC Pourny, C Weber, B de Laroche, G Pichon, A Seffert, P Hayat, M Zambon, E Chollet, P Van Praagh, I

Citation: A. Adenis et al., Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French adjuvant study group 05 randomized trial, J CL ONCOL, 19(3), 2001, pp. 602-611

Authors: Harousseau, JL Witz, B Lioure, B Hunault-Berger, M Desablens, B Delain, M Guilhot, F Le Prise, PY Abgrall, JF Deconinck, E Guyotat, D Vilque, JP Casassus, P Tournilhac, O Audhuy, B Solary, E

Citation: Jl. Harousseau et al., Granulocyte colony-stimulating factor after intensive consolidation chemotherapy in acute myeloid leukemia: Results of a randomized trial of the Groupe Ouest-Est Leucemies Aigues Myeloblastiques, J CL ONCOL, 18(4), 2000, pp. 780-787

Authors: Hamid, D Duclos, B Barats, JC Prevot, G Hummel, M Baldauf, JJ Brettes, P Giron, C Maloisel, F Lioure, B Herbrecht, R Audhuy, B Bergerat, JP Oberling, F Dufour, P

Citation: D. Hamid et al., Prognostic factors in ovarian carcinoma in complete histologic remission at second-look surgery, INT J GYN C, 9(3), 1999, pp. 231-237

Authors: Viens, P Palangie, T Janvier, M Fabbro, M Roche, H Delozier, T Labat, JP Linassier, C Audhuy, B Feuilhade, F Costa, B Delva, R Cure, H Rousseau, F Guillot, A Mousseau, M Ferrero, JM Bardou, VJ Jacquemier, J Pouillart, P

Citation: P. Viens et al., First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial), BR J CANC, 81(3), 1999, pp. 449-456